加载中
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
最新数据
US$99.26
−US$0.61 · -0.61%
盘中时间采用ET。市场数据可能有所延迟。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
盘中时间采用ET。市场数据可能有所延迟。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 2670.6万 USD | 2594.7万 USD | 1100.1万 USD | 871.1万 USD |
| 毛利 | — | −2670.6万 USD | −2594.7万 USD | −1100.1万 USD | −871.1万 USD |
| 研究与开发 | 1.82亿 USD | 1.26亿 USD | 2.06亿 USD | 2.68亿 USD | 2.17亿 USD |
| 销售、一般及管理费用 | 5201.5万 USD | 3404.8万 USD | 7102.3万 USD | 6278.7万 USD | 4100万 USD |
| 营业费用 | 2.34亿 USD | 1.6亿 USD | 2.51亿 USD | 3.3亿 USD | 2.58亿 USD |
| 利息收入 | 451.7万 USD | 1114.8万 USD | 1673.3万 USD | 707.1万 USD | 29.8万 USD |
| 利息支出 | — | — | 1.3万 USD | 1.8万 USD | 2.2万 USD |
| 折旧和摊销 | 2632万 USD | 2670.6万 USD | 2594.7万 USD | 1100.1万 USD | 871.1万 USD |
| 营业利润 | −2.34亿 USD | −1.87亿 USD | −2.77亿 USD | −3.41亿 USD | −2.67亿 USD |
| 净利润 | −2.3亿 USD | −1.76亿 USD | −2.6亿 USD | −3.34亿 USD | −2.67亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI1.26亿1.28%98.74亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1.03亿0.13%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI4818.83万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Biotechnology ETFIBB4508.97万0.42%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell 2000 Growth ETFIWO3635.26万0.26%139.17亿 USD0.24%US$353.71-0.86%
Schwab U.S. Small-Cap ETFSCHA2092.7万0.10%218.24亿 USD0.03%US$32.66-0.40%
Vanguard Extended Market ETFVXF1784.69万0.02%954亿 USD0.05%US$233.52-0.63%
Fidelity Enhanced Small Cap ETFFESM1539.09万0.23%64.1亿 USD0.28%US$45.24-0.48%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
